about
From single-gene to multiplex analysis in lung cancer, challenges and accomplishments: a review of a single institution's experience.Targeting the estrogen pathway for the treatment and prevention of lung cancerThe role of estrogen, progesterone and aromatase in human non-small-cell lung cancerRecent advances and clinical implications of the micropapillary histological subtype in lung adenocarcinomasImmunotherapy treatments for small-cell lung cancer: past, present and future.The evolving role of the pathologist in the management of lung cancer.Assessing the benefits and harms of low-dose computed tomography screening for lung cancerTargeted therapy for squamous cell lung cancer.Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatmentCirculating cell-free DNA: a potential biomarker in lung cancerThe evaluation of cancer control interventions in lung cancer using the Canadian Cancer Risk Management ModelLiquid biopsy and NSCLCNew directions in mesothelioma treatmentNovel insights into the pathophysiology and treatment of malignant pleural mesotheliomaCombining chemotherapy and checkpoint blockade in thoracic cancer: how to proceed?Lung stereotactic body radiotherapy after past ablative therapy: a single institution case seriesStereotactic body radiation therapy in early-stage NSCLC: historical review, contemporary evidence and future implicationsTargeting claudin-3 suppresses stem cell-like phenotype in nonsquamous non-small-cell lung carcinomaWe need to educate young lung cancer patients about menopause riskMeasurement of quality of life in second-line patients with advanced NSCLC without targetable mutations: a review.First-line treatment of nonsquamous NSCLC using gemcitabine: a retrospective study of real-life practice.PET/CT and brain MRI role in staging NSCLC: prospective assessment of the accuracy, reliability and cost-effectiveness.Lung cancer: new tools for surgery.Severe intestinal ischemia during chemotherapy for small cell lung cancer.Interview: developing therapies for lung cancer.Cost-effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression.Recent results of immunotherapy and perspectives for advanced NSCLC.DNA repair in lung cancer: potential not yet reached.Treatment for non-small-cell lung cancer and circulating tumor cells.The route to diagnosis: emergency presentation of lung cancer.Nintedanib in advanced NSCLC: management of adverse events.Are neuroendocrine negative small cell lung cancer and large cell neuroendocrine carcinoma with WT RB1 two faces of the same entity?Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancerPembrolizumab-induced necrotizing myositis in a patient with metastatic non-small-cell lung cancer: a case reportClinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitorsNeurotrophic tyrosine kinase gene fusions: another opportunity for targeting in lung cancerCommunity hospital experience using electromagnetic navigation bronchoscopy system integrating tidal volume computed tomography mappingCurative intent therapy in oligometastatic lung cancer with an unresectable primary with N3 nodes: case report and review of the literatureClinical and research priorities for combined modality therapy in stage III NSCLCLymphnodal micrometastases in NSCLC: where do we stand?
P1433
Q28385559-B0BF0E11-1D00-427C-8273-D5C2B8249E64Q28397456-C4C35885-BFC8-4F44-909B-E04A646F7727Q28397662-5F079898-875D-4354-ABB9-8E174ABD132DQ34141249-2AF97948-74A5-4B78-B7C1-DFF953B0A774Q35904003-91AF42BF-CBFC-4831-B75C-AF49B934C871Q35951079-5F437EEB-1589-4671-9613-70534F5DA842Q36326625-56CED972-56B8-4378-B653-1097A16A94CAQ37096910-AF4AF788-FF62-4BCE-B158-FABDC205A4A3Q38262500-F8BA3DE3-D38F-4620-87B5-54686EF7B57FQ57306273-439BF756-8DDB-4A71-9521-1E2830A709EEQ58287526-5198FDD6-FD65-44C9-8FC2-F7239BE2444DQ61548344-F7DB9419-9DA7-4B98-8A8F-3F0456EBCE80Q61627786-BCA033DD-A93B-4209-B8FD-53B43AE0BABEQ61627792-726EC51C-169D-40EF-BE8E-1B4B65B336FBQ61627858-5F4A3068-5FBA-4E08-9ABC-B7C454E5F1EAQ61815135-38D5AAC2-2797-42D9-BB69-D24B2B6218FEQ64096283-B0F131D4-AFD9-47D6-9AD2-9872C440E554Q64101983-7DB17079-F9F9-4607-B0DA-1A5833AEC0B1Q64237098-B5897AFD-A10B-4EDE-B797-53E3A0BA7A07Q64883385-12C86E1E-99D6-43EF-81C2-8C0749E55DE7Q64894343-51AD103C-4C37-40EE-848D-D3F18401C369Q64900960-C3CA9967-ED41-4634-A15C-E07D94D1572AQ64917163-4B4E145F-FF8C-4531-A583-DAFE534AF4DCQ64926224-C211ACCE-A351-4C07-B4DA-41F7864E8A8EQ64927663-9D62C740-0E63-48EF-B533-19CD7CFAACECQ64938910-6A20C872-D953-4E4A-85DD-6DF446092C0BQ64950978-3A115107-7606-406F-A3FB-E210247B9538Q64966054-320ADD32-B722-4EC6-905C-AA21D22473A0Q64973779-55CDBB9E-97FA-40C0-8CD5-3E2411886EB7Q64982970-F9813B47-B302-4509-B5C0-5BC3DEF40C23Q64985756-97CD5BD3-C80F-4FA1-B992-A169EC2C276EQ90912300-0B6C3BEB-070B-413F-BA8F-0B2A9F892887Q90912304-A179457C-DF1F-431F-A258-4DB49C9506BDQ90912306-B2E3712A-5EA6-441A-B0C6-F069973ED2AFQ90912310-0B1E0F10-90FB-4CD0-B548-EDCAFA6E83F8Q91046882-CE8FAE61-A4CA-4943-A7DA-5E9F6AD920E4Q91046888-5C1E3C04-FC22-4809-ACC0-F918F6CF6D53Q91046892-300FC0A8-E28F-422D-B9EA-88A6A8FDBA57Q91046898-0FBF461D-7B05-415C-A3B1-5FF54AB7B6B3Q91046900-04ED6322-11ED-4BE2-918E-0C5EF75F094F
P1433
description
czasopismo naukowe
@pl
journal
@en
revista científica
@es
wetenschappelijk tijdschrift
@nl
wissenschaftliche Fachzeitschrift
@de
name
Lung cancer management
@ast
Lung cancer management
@en
Lung cancer management
@es
Lung cancer management
@nl
type
label
Lung cancer management
@ast
Lung cancer management
@en
Lung cancer management
@es
Lung cancer management
@nl
altLabel
Lung Cancer Manag
@en
prefLabel
Lung cancer management
@ast
Lung cancer management
@en
Lung cancer management
@es
Lung cancer management
@nl
P3181
P1055
P1156
21100780211
P1476
Lung cancer management
@en